Liquorology: A tool in the diagnosis of multiple sclerosis and other neurodegenerative and demyelinating diseases
DOI:
https://doi.org/10.33448/rsd-v14i12.49815Keywords:
Cerebrospinal fluid, Multiple sclerosis, Demyelinating diseases, Oligoclonal bands.Abstract
Neurodegenerative diseases are characterized by their insidious onset and the severe complications they cause during their course, resulting in many disabilities and even death. This study aimed to evaluate the application of cerebrospinal fluid (CSF) laboratory analyses in the diagnosis and prognosis of multiple sclerosis and other demyelinating diseases. This research is a narrative literature review, which searched databases such as SciELO (Scientific Electronic Library Online), BVS (Virtual Health Library), Google Scholar, and PubMed for current academic articles that supported this study. The studies unanimously demonstrated the importance of CSF analysis in the diagnosis of neurodegenerative diseases such as multiple sclerosis, particularly in the assessment of intrathecal albumin synthesis and the application of the Reiber diagram to distinguish whether the elevation of immunoglobulins is due to passive diffusion due to blood-brain barrier damage or to intrathecal synthesis, as is characteristic of multiple sclerosis. Technological and scientific advances in CSF analysis make it a central tool in the diagnosis and prognosis of neurodegenerative diseases such as multiple sclerosis.
References
Barros, C., Alberro, A., & Fernandes, A. (2024). Microglia and immune cells interactions in multiple sclerosis cognitive impairment: a postmortem study. Journal of Neuroinflammation, 21, Artigo 332.
Coutinho-Costa, V. G., et al. (2023). Central nervous system demyelinating diseases: glial cells, autoimmunity, and etiopathogenesis. Frontiers in Immunology, 14.
Domingues, R. B., et al. (2024). Concordância entre bandas oligoclonais e o índice Kappa na avaliação da síntese intratecal de imunoglobulina G em pacientes com suspeita de esclerose múltipla. Arquivos de Neuro-Psiquiatria, 82(4), 307–314.
Domingues, R. B., et al. (2020). Quantitative and qualitative evaluation of IgG synthesis in cerebrospinal fluid of patients with multiple sclerosis. Journal of Neuroimmunology, 346, 577321. https://doi.org/10.1016/j.jneuroim.2020.577321
Gebka-Kępińska, B., et al. (2024). Cytokine profiling in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. Journal of Neuroimmunology.
Gottle, P., Groh, J., Reiche, L., Gruchot, J., Rychlik, N., Werner, L., ... Küry, P. (2023). Teriflunomide as a therapeutic means for myelin repair. Journal of Neuroinflammation, 20, 7.
Gottlieb, A., Pham, H. P. T., Saltarrelli, J. G., & Lindsey, J. W. (2024). Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells. Proceedings of the National Academy of Sciences, 121(3), e2315857121.
Hosny, H. S., et al. (2023). Predictors of severity and outcome of multiple sclerosis relapses. BMC Neurology, 23(1), 1–9.
Johansson, E., et al. (2025). Impact of lifestyle factors post-infectious mononucleosis on multiple sclerosis risk. European Journal of Epidemiology, 40(3), 339–346. https://doi.org/10.1007/s10654-025-01212-1
Khinowska-Łyszczarz, A., Guo, Y., & Lucchinetti, C. F. (2025). Update on pathology of central nervous system inflammatory demyelinating diseases. Neurology.
Kaya, İ. İ., et al. (2025). The effect of demographic features and environmental risk factors on the clinical course in patients with multiple sclerosis. Turkish Journal of Neurology, 31(2), 118–127. https://doi.org/10.55697/tnd.2025.211
Khalil, M., & Zetterberg, H. (2025). Novel cerebrospinal fluid biomarkers in multiple sclerosis and related disorders. Nature Reviews Neurology, 21.
Klineova, S., & Lublin, F. D. (2019). Clinical course of multiple sclerosis. Current Opinion in Neurology, 31(3), 239–245.
Liu, L., Guo, K., & Yang, D. (2025). Advances in biomarkers for optic neuritis and neuromyelitis optica spectrum disorders: a multi-omics perspective. Frontiers in Neurology, 16, 1559172.
Liu, Y., Wang, H., & Zhang, Q. (2024). Clinical utility of cerebrospinal fluid analysis in inflammatory demyelinating diseases of the CNS. Journal of Neurology, 271(7), 3350–3362.
Mercer, O., Quilichini, P. P., Magalon, K., Gil, F., Ghestem, A., Richard, F., Boudier, T., Cayre, M., & Durbec, P. (2023). Transient demyelination causes long-term cognitive impairment, myelin alteration and network synchrony defects. Nature Communications, 14(1), 1–15. https://doi.org/10.1038/s41467-023-40251-3
Multz, R. A., Jamshidi, P., & Ahrendsen, J. T. (2025). Multiple sclerosis: a practical review for pathologists. Journal of Pathology and Translational Medicine, 59(4), 203–213.
Padrón-González, A. J., et al. (2019). Empleo del Reibergrama en manifestaciones neurológicas. Revista Cubana de Medicina, 56(5), 1–7.
Qin, D., Li, D., & Guo, S. (2023). Ferroptosis and central nervous system demyelinating diseases. Journal of Neurochemistry, 165(6), 759–771.
Ramo-Tello, C., Tintoré, M., Rovira, A., et al. (2021). Recommendations for the diagnosis and treatment of multiple sclerosis relapses. Multiple Sclerosis Journal, 27(1), 3–13.
Rabaneda-Lombarte, N., Teniente-Serra, A., Massuet-Vilamajó, A., Ramo-Tello, C., & Presas-Rodríguez, S. (2024). Case report: Tumefactive demyelinating lesions after the second cycle of alemtuzumab in multiple sclerosis; immune cell profile and biomarkers. Frontiers in Immunology.
Rother, E. T. (2007). Revisão sistemática x revisão narrativa. Acta Paulista de Enfermagem. 20(2), 5-6.
Salzer, J., et al. (2024). Cerebrospinal fluid markers in demyelinating diseases: from diagnosis to prognosis. Frontiers in Immunology, 15.
Snyder, H. (2019). Literature Review as a Research Methodology: An Overview and Guidelines. Journal of Business Research, 104, 333-339. https://doi.org/10.1016/j.jbusres.2019.07.039.
Pereira, A. S. (2018). Metodologia da pesquisa científica. [free ebook]. Santa Maria. Editora da UFSM.
Pontieri, L., et al. (2024). Patterns and predictors of multiple sclerosis phenotype transition. Brain Communications, 6(6), Artigo fcae422.
Van de Burgt, N. A., et al. (2025). Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms. Frontiers in Neurology, 16, Artigo 1593042. https://doi.org/10.3389/fneur.2025.1593042
Wang, L. Y., et al. (2025). Emerging epidemiological trends of multiple sclerosis: From risk factors to prevention. Frontiers in Neurology, 16, Artigo 1616245.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Laura Maria de Araújo Pereira, Talyta Valeria Siqueira do Monte Guedes, Rafaell Batista Pereira, Davi Abrantes Lucena Messias, Marfran José Cunha Urtiga, Davi Rodrigues Vieira, Samuel da Costa Chaves Trindade Martins, José Guedes da Silva Júnior
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
